Immuneering Appoints Andrew Gengos as Chief Financial Officer

About this update from Immuneering Corporation

- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion. At Immuneering, Mr. Gengos will oversee financial strategy, capital allocation, investor relations, business development, and corporate development activities as the company advances atebimetinib, its lead oncology candidate in Phase 3, and a pipeline of other deep cyclic inhibitors. “Andrew is a proven biotechnology executive with a strong track record of helping innovative companies navigate critical stages of growth and value creation,” said Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. “His experience as a CFO, business development leader, and strategic advisor will be invaluable as we advance our clinical programs and prepare for the next phase of Immuneering's growth. We are delighted to welcome Andrew to our leadership team.” “I am thrilled to join Immuneering at such an exciting time in the company's development,” said Andrew Gengos. “Atebimetinib is now a Phase 3 candidate in first-line pancreatic cancer, supported by recently presented survival and tolerability data that are highly encouraging in a disease where new treatment options are urgently needed. A growing body of data supports the potential of Immuneering’s differentiated deep cyclic inhibitor technology to benefit patients with RAS, RAF, and other MAPK-driven cancers. I believe we are in the early chapters of this compelling story and look forward to working with Immuneering’s leadership team and Board to advance atebimetinib through late-stage development and create value for patients and shareholders alike.” Prior to joining Terns, Mr. Gengos served as Chief Financial Officer and Chief Business Officer of Athira Pharma, Inc. (now LeonaBio, Inc.). Previously, he served as Chief Business Officer of Cyteir Therapeutics, Inc., where he led the f...

View stock analysis, news, and events for Immuneering Corporation